2020
Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration
Hung P, Hsu SH, Wang SY. Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration. Value In Health 2020, 23: 697-704. PMID: 32540226, DOI: 10.1016/j.jval.2020.01.021.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseCongestive heart failureEOL expendituresHospice staysEnd Results-Medicare dataLonger hospice staysObstructive pulmonary diseaseMonths of lifeDays of lifeDistinct disease trajectoriesPatient disease groupsCancer decedentsDifferential associationsHeart failureAggressive endPulmonary diseaseHospice lengthMedical covariatesCancer patientsHospice useDisease groupClinical conditionsLife careDisease trajectoriesPatients
2017
Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure
Dang W, Yi A, Jhamnani S, Wang SY. Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure. The American Journal Of Cardiology 2017, 120: 1338-1343. PMID: 28842145, DOI: 10.1016/j.amjcard.2017.06.071.Peer-Reviewed Original ResearchConceptsMultidisciplinary management programIncremental cost-effectiveness ratioUsual careLife yearsHeart failureExercise training programHealthcare payer perspectiveCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness thresholdCurrent cost-effectiveness thresholdsPayer perspectiveHealthcare costsHealth outcomesTraining programSocietal perspectiveSignificant healthFinancial burdenPatientsManagement programETPFailureYearsCare
2014
Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival
Wang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP, Chen J. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Research And Treatment 2014, 146: 411-419. PMID: 24951268, DOI: 10.1007/s10549-014-3029-0.Peer-Reviewed Original ResearchConceptsCardiovascular eventsEarly discontinuationTrastuzumab treatmentCause mortalityTrastuzumab therapyTrastuzumab discontinuationBreast cancerCox proportional hazards modelContinuous trastuzumab treatmentAdverse cardiovascular eventsPopulation-based cohortFemale Medicare beneficiariesHigher mortality riskProportional hazards modelNon-significant increaseCardiovascular complicationsOlder patientsOverall survivalHeart failureAtrial fibrillationDiscontinuationMortality riskOlder womenMedicare beneficiariesHazards model